Immunotherapy News and Research

Latest Immunotherapy News and Research

Two synergistic therapies allow solid tumors to act as their own cancer-fighting vaccine

Two synergistic therapies allow solid tumors to act as their own cancer-fighting vaccine

Rheumatoid arthritis and switching TNFis: an interview with Professor Paul Emery, University of Leeds

Rheumatoid arthritis and switching TNFis: an interview with Professor Paul Emery, University of Leeds

Thirteen graduate students to receive 2014 Harold M. Weintraub Graduate Student Award

Thirteen graduate students to receive 2014 Harold M. Weintraub Graduate Student Award

A pill may provide hope to relapsed leukemia and lymphoma patients

A pill may provide hope to relapsed leukemia and lymphoma patients

BWH researchers explore newer approaches to treat Alzheimer's disease

BWH researchers explore newer approaches to treat Alzheimer's disease

Ludwig, Agenus to advance three monoclonal antibody checkpoint modulators into preclinical development

Ludwig, Agenus to advance three monoclonal antibody checkpoint modulators into preclinical development

Researcher wins grant from NCI to continue developing new therapy for bladder cancer

Researcher wins grant from NCI to continue developing new therapy for bladder cancer

Novel cancer immunotherapy approach may provide new weapon against most deadly tumors

Novel cancer immunotherapy approach may provide new weapon against most deadly tumors

Agenus reports net loss attributable to common stockholders of $5.8 million for Q4 2013

Agenus reports net loss attributable to common stockholders of $5.8 million for Q4 2013

Merck reports results from Phase 2b study of investigational house dust mite sublingual immunotherapy tablet

Merck reports results from Phase 2b study of investigational house dust mite sublingual immunotherapy tablet

Eisai collaborates with Biogen Idec to develop and commercialize treatment options for AD

Eisai collaborates with Biogen Idec to develop and commercialize treatment options for AD

Local hyperthermia treatment induces mechanism of anti-tumor immune resistance

Local hyperthermia treatment induces mechanism of anti-tumor immune resistance

Experimental drug nivolumab shrinks tumors in patients with advanced melanoma

Experimental drug nivolumab shrinks tumors in patients with advanced melanoma

Dendreon plans to make PROVENGE available in Europe

Dendreon plans to make PROVENGE available in Europe

Food allergy increases among black children, say researchers

Food allergy increases among black children, say researchers

Washington University professor to receive AACR-CRI Lloyd J. Old Award in Cancer Immunology

Washington University professor to receive AACR-CRI Lloyd J. Old Award in Cancer Immunology

Asthma drug accelerates desensitization in patients with food allergies to several foods

Asthma drug accelerates desensitization in patients with food allergies to several foods

Fred Hutchinson, SCCA researchers receive Seattle Business Magazine's 2014 Leaders in Health Care Awards

Fred Hutchinson, SCCA researchers receive Seattle Business Magazine's 2014 Leaders in Health Care Awards

Biothera’s Phase 2b clinical trial in NSCLC presented at International Association for the Study of Lung Cancer

Biothera’s Phase 2b clinical trial in NSCLC presented at International Association for the Study of Lung Cancer

NCI recommends renewal for Wistar's Support Grant with award of $14.9M

NCI recommends renewal for Wistar's Support Grant with award of $14.9M

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.